HealthPartners Institute | MedPath Search

Found 198 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "HealthPartners Institute"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Phase 2

Terminated

Conditions: Melanoma
Small Cell Lung Cancer
Non-small Cell Lung Cancer, Non-squamous
Prostate Cancer
Non-small Cell Lung Cancer, Squamous
Esophageal Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: ladiratuzumab vedotin
Drug: pembrolizumab

First Posted Date: 2019-07-25

Last Posted Date: 2025-03-10

Lead Sponsor: Seagen Inc.

Target Recruit Count: 205

Registration Number: NCT04032704

Locations: 🇺🇸
FirstHealth of the Carolinas, Pinehurst, North Carolina, United States
🇺🇸
Adventist Health White Memorial, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 63 locations

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

Phase 2

Terminated

Conditions: Type1diabetes

Interventions: Device: SipNose intranasal device
Drug: Regular insulin (Humulin-R), intranasal route

First Posted Date: 2019-07-23

Last Posted Date: 2021-05-18

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 4

Registration Number: NCT04028960

Locations: 🇺🇸
Health Partners Institute dba International Diabetes Center, Minneapolis, Minnesota, United States

Comprehensive Cardiac Rehabilitation Feasibility After Stroke

Not Applicable

Completed

Conditions: Stroke, Ischemic

Interventions: Behavioral: Exercise

First Posted Date: 2019-05-09

Last Posted Date: 2023-05-16

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 17

Registration Number: NCT03944668

Locations: 🇺🇸
Regions Hospital, Saint Paul, Minnesota, United States
🇺🇸
Regions Hospital Outpatient Cardiopulmonary Rehabilitation Clinic, Saint Paul, Minnesota, United States
🇺🇸
HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States

PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer

Phase 1

Withdrawn

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Nivolumab

First Posted Date: 2019-04-25

Last Posted Date: 2020-05-07

Lead Sponsor: HealthPartners Institute

Registration Number: NCT03927248

Chronic Kidney Disease Clinical Decision Support

Not Applicable

Completed

Conditions: Diabetes
Hypertension
Chronic Kidney Diseases

Interventions: Other: CKD enhanced clinical decision support

First Posted Date: 2019-03-26

Last Posted Date: 2022-12-01

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 6295

Registration Number: NCT03890588

Locations: 🇺🇸
HealthPartners Care System, Bloomington, Minnesota, United States

Rehabilitation Following Reverse Total Shoulder Arthroplasty

Not Applicable

Recruiting

Conditions: Shoulder Osteoarthritis

Interventions: Other: Rehabilitiation

First Posted Date: 2019-01-15

Last Posted Date: 2024-05-02

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 74

Registration Number: NCT03804853

Locations: 🇺🇸
TRIA Orthopaedic Center, Bloomington, Minnesota, United States

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

Active, not recruiting

Conditions: Colorectal Cancer

First Posted Date: 2018-12-28

Last Posted Date: 2025-04-24

Lead Sponsor: Exact Sciences Corporation

Target Recruit Count: 1500

Registration Number: NCT03789162

Locations: 🇺🇸
Tilda Research, Laguna Hills, California, United States
🇺🇸
Guardian Angel Research Center, Tampa, Florida, United States
🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States

and more 40 locations

Medication Adherence Clinical Decision Support

Not Applicable

Completed

Conditions: Hyperlipidemia
Hypertension
Diabetes
Medication Nonadherence

Interventions: Other: Adherence Intervention

First Posted Date: 2018-11-20

Last Posted Date: 2024-02-26

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 5421

Registration Number: NCT03748420

Locations: 🇺🇸
HealthPartners Care System, Bloomington, Minnesota, United States

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1

Completed

Conditions: TNBC - Triple-Negative Breast Cancer
Ovarian Cancer

Interventions: Drug: Etrumadenant
Drug: nanoparticle albumin-bound paclitaxel (NP)
Drug: IPI-549
Drug: Pegylated liposomal doxorubicin (PLD)

First Posted Date: 2018-10-25

Last Posted Date: 2024-05-24

Lead Sponsor: Arcus Biosciences, Inc.

Target Recruit Count: 35

Registration Number: NCT03719326

Locations: 🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
🇺🇸
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸
Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

and more 24 locations

Evaluation of 19-gauge vs 21-gauge EBUS TBNA in Assessing Thoracic Lymphadenopathy

Not Applicable

Completed

Conditions: Enlarged Lymph Nodes (Excluding Infective)

Interventions: Device: EBUS TBNA

First Posted Date: 2018-09-05

Last Posted Date: 2023-03-21

Lead Sponsor: HealthPartners Institute

Target Recruit Count: 60

Registration Number: NCT03657849

Locations: 🇺🇸
Regions Hospital, Saint Paul, Minnesota, United States